阿伐斯汀联合氯雷他定治疗慢性难治性荨麻疹的有效性

目的 探讨阿伐斯汀加氯雷他定治疗慢性难治性荨麻疹的有效性。方法 选取滕州市柴胡店镇卫 生院2022年1月-2023年1月收治的88例慢性难治性荨麻疹患者，采用随机数字表法将其分为参照组与试验 组，各44例。参照组应用氯雷他定治疗，试验组采取阿伐斯汀联合氯雷他定治疗，比较两组症状积分；实 验室相关指标、生活质量。结果 试验组干预后症状积分低于参照组，差异有统计学意义（P＜0.05）；试 验组干预后IgE、WBC低于参照组，5-HT高于参照组，差异有统计学意义（P＜0.05）；试验组干预后生 活质量评分高于参照组，差异有统计学意义（P＜0.05）。结论 慢性难治性荨麻疹治疗中，联合应用阿伐 斯汀、氯雷他定有助于改善患者的免疫功能，加快其症状缓解速度，提高其生活质量。

Efficacy of Acrivastine Combined with Loratadine in the Treatment of Chronic Refractory Urticaria

Objective To investigate the efficacy of acrivastine combined with loratadine in the treatment of chronic refractory urticaria. Methods A total of 88 patients with chronic refractory urticaria were selected from January 2022 to January 2023 in Chaihudian Town Hospital of Tengzhou City, and they were divided into control group and experimental group by random number table method, with 44 patients in each group. The reference group was treated with loratadine, and the experimental group was treated with acrivastine combined with loratadine. The symptom scores, laboratory related indicators and quality of life were compared between the two groups. Results After intervention, the symptom score of the experimental group was lower than that of the reference group, the difference was statistically significant (P